Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

Abstract

Hematologic malignancies are predominantly treated with chemotherapy or a combination of chemotherapy with monoclonal antibodies. Current treatment regimens often are not satisfactory due to severe side effects and a substantial proportion of relapsed patients. This has prompted the development of better tolerated and more efficacious immunotherapeutic strategies for the treatment of lymphoma and leukemia. With blinatumomab (MT103) a first antibody, which can potentially engage all cytotoxic T cells of a patient for tumor cell lysis, is now available for clinical evaluation. Blinatumomab is a single-chain bispecific antibody construct with specificity for CD19 and CD3 belonging to the class of bispecific T cell engager. Here, we review the current progress in development of blinatumomab for treatment of patients with CD19-expressing hematological malignancies.

• Authors: Dirk Nagorsen, Ralf Bargou, Dominik Ruttinger, Peter Kufer, Patrick A Baeuerle, Gerhard Zugmaier
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 50 Issue 6 Pg. 886-91 (Jun 2009) ISSN: 1029-2403 [Electronic] United States
• PMID: 19455460 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Bispecific
• Antigens, CD19
• blinatumomab

Topics

• Antibodies, Bispecific (therapeutic use)
• Antigens, CD19 (immunology)
• B-Lymphocytes (cytology, immunology)
• Cytotoxicity, Immunologic (drug effects, immunology)
• Humans
• Immunotherapy (methods)
• Leukemia (immunology, therapy)
• Lymphoma (immunology, therapy)
• Models, Immunological
• T-Lymphocytes (cytology, immunology)